Atogepant, the first oral preventive treatment for chronic migraine

Lancet. 2023 Sep 2;402(10404):748-749. doi: 10.1016/S0140-6736(23)01462-9. Epub 2023 Jul 26.

Authors

Kristian A Haanes¹, Lars Edvinsson²

Affiliations

¹ Department of Clinical Experimental Research, Glostrup Research Institute, Rigshospitalet-Glostrup, 2600 Glostrup, Denmark. Electronic address: kristian.agmund.haanes@regionh.dk.
² Department of Clinical Experimental Research, Glostrup Research Institute, Rigshospitalet-Glostrup, 2600 Glostrup, Denmark; Department of Internal Medicine, Lund University Hospital, Lund, Sweden.

PMID: 37516124
DOI: 10.1016/S0140-6736(23)01462-9

No abstract available

Publication types

Comment

MeSH terms

Administration, Oral
Calcitonin Gene-Related Peptide
Humans
Migraine Disorders* / drug therapy
Migraine Disorders* / prevention & control
Piperidines* / therapeutic use

Substances

atogepant
Piperidines
Calcitonin Gene-Related Peptide